News

Novo backs AMD drug
Enlarge image

BusinessDenmark

Novo backs AMD drug

30.05.2013 - Danish Novo A/S has secured royalties on an upcoming competitor treatment to the age-related macular degeneration drug Lucentis.

In total, the Danish injected US$175m to push Phase III development of Ophtotec’s AMD drug Fovista (E10030). The company led a US$50m Series C financing and secured a share on future royalties with the anti-PDGF pegylated aptamer in exchange for US$125m.

In Phase IIb studies, dosing 449 patients with wet AMD with 6 monthly injections of Fovista plus Lucentis in the eye led to an 62% improvement of vision compared to Lucentis monotherapy after 6 months. Last year Roche’s VEGF-targeting angiogenesis blocker, which is distributed in Europe by Novartis, made more that 1.5bn in sales.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/novo-backs-amd-drug.html

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • ERYTECH PHARMA (F)39.50 EUR9.45%
  • PAION (D)2.69 EUR8.47%

FLOP

  • BAVARIAN NORDIC (D)40.26 EUR-10.69%
  • ZELTIA (E)3.69 EUR-8.44%
  • TIGENIX (B)0.73 EUR-7.59%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)81.03 EUR53.6%
  • IXICO (UK)34.00 GBP41.7%

FLOP

  • BIOTEST (D)27.24 EUR-60.8%
  • BIOTECH PHARMACON (N)9.43 NOK-46.1%
  • TRANSGENE (F)2.80 EUR-23.9%

TOP

  • ADOCIA (F)88.74 EUR587.4%
  • DBV TECHNOLOGIES (F)81.03 EUR328.7%
  • FORMYCON (D)28.70 EUR315.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.70 SEK-71.6%
  • NEOVACS (F)1.01 EUR-69.5%

No liability assumed, Date: 03.08.2015